149 related articles for article (PubMed ID: 36510406)
1. Is the assumption of waning of treatment effect applied consistently across NICE technology appraisals? A case-study focusing on disease-modifying therapies for treatment of multiple sclerosis.
Armoiry X; Wang-Steverding X; Connock M; Grove A; Clarke A; Arun T; Counsell C; Auguste P
Int J Technol Assess Health Care; 2022 Dec; 38(1):e83. PubMed ID: 36510406
[TBL] [Abstract][Full Text] [Related]
2. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
3. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
4. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
Gallacher D; Auguste P; Connock M
Int J Technol Assess Health Care; 2019 Jan; 35(2):160-167. PubMed ID: 31017564
[TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
[TBL] [Abstract][Full Text] [Related]
6. Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.
Hernandez L; O'Donnell M; Postma M
Pharmacoeconomics; 2018 Oct; 36(10):1223-1252. PubMed ID: 29971666
[TBL] [Abstract][Full Text] [Related]
7. Treatment Effect Waning Assumptions: A Review of National Institute of Health and Care Excellence Technology Appraisals.
Trigg LA; Melendez-Torres GJ; Abdelsabour A; Lee D
Value Health; 2024 Apr; ():. PubMed ID: 38679289
[TBL] [Abstract][Full Text] [Related]
8. Audit of data redaction practices in NICE technology appraisals from 1999 to 2019.
Osipenko L
BMJ Open; 2021 Oct; 11(10):e051812. PubMed ID: 34615680
[TBL] [Abstract][Full Text] [Related]
9. Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy.
Kang J; Cairns J
BMC Cancer; 2022 Dec; 22(1):1268. PubMed ID: 36471259
[TBL] [Abstract][Full Text] [Related]
10. Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals.
Polak TB; Cucchi DGJ; van Rosmalen J; Uyl-de Groot CA
BMJ Open; 2022 Jan; 12(1):e052186. PubMed ID: 34992108
[TBL] [Abstract][Full Text] [Related]
11. Health Technology Assessment-Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact.
Schaefer R; Hernández D; Bärnighausen T; Kolominsky-Rabas P; Schlander M
Value Health; 2023 Jul; 26(7):1032-1044. PubMed ID: 36921901
[TBL] [Abstract][Full Text] [Related]
12. NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence.
Bullement A; Taylor M; McMordie ST; Waters E; Hatswell AJ
Pharmacoeconomics; 2019 Nov; 37(11):1383-1390. PubMed ID: 31250397
[TBL] [Abstract][Full Text] [Related]
13. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
[TBL] [Abstract][Full Text] [Related]
14. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
Schaefer R; Schlander M
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
[No Abstract] [Full Text] [Related]
15. The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process.
Carroll C; Kaltenthaler E; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Value Health; 2017 Jun; 20(6):785-791. PubMed ID: 28577696
[TBL] [Abstract][Full Text] [Related]
16. When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.
Longworth L; Youn J; Bojke L; Palmer S; Griffin S; Spackman E; Claxton K
Pharmacoeconomics; 2013 Feb; 31(2):137-49. PubMed ID: 23329429
[TBL] [Abstract][Full Text] [Related]
17. A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement.
Bell Gorrod H; Kearns B; Stevens J; Thokala P; Labeit A; Latimer N; Tyas D; Sowdani A
Med Decis Making; 2019 Nov; 39(8):899-909. PubMed ID: 31707911
[No Abstract] [Full Text] [Related]
18. Understanding the National Institute for Health and Care Excellence Severity Premium: Exploring Its Implementation and the Implications for Decision Making and Patient Access.
Njoroge MW; Walton M; Hodgson R
Value Health; 2024 Jun; 27(6):730-736. PubMed ID: 38447743
[TBL] [Abstract][Full Text] [Related]
19. Cross-sectional analysis of use of real-world data in single technology appraisals of oncological medicine by the National Institute for Health and Care Excellence in 2011-2021.
Kang J; Cairns J
BMJ Open; 2024 Mar; 14(3):e077297. PubMed ID: 38485485
[TBL] [Abstract][Full Text] [Related]
20. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
Hashem F; Calnan MW; Brown PR
Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]